The LSD1 inhibitors which are under clinical trial mainly focus on treatment of AML and MDS, and only one LSD1 inhibitor, CC-90011 is undergoing clinical trials for NHL therapy. Here, KDM1A is linked to non-Hodgkin lymphoma.